Wolfgang Hiddemann

Author PubWeight™ 244.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003 17.67
2 A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2007 5.18
3 Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002 4.35
4 Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002 3.97
5 Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005 3.90
6 Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005 3.61
7 Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2008 3.44
8 Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 2002 3.05
9 The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004 3.04
10 Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006 2.83
11 Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010 2.66
12 Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010 2.62
13 Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2004 2.50
14 An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008 2.46
15 Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006 2.22
16 Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004 2.21
17 Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2002 2.12
18 Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006 2.06
19 Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2008 2.01
20 Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005 1.96
21 Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012 1.91
22 High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007 1.89
23 Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 2006 1.88
24 KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2005 1.85
25 Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2009 1.84
26 Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005 1.76
27 Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006 1.75
28 Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 2006 1.74
29 Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2009 1.73
30 Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004 1.73
31 Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferation. J Cell Biol 2005 1.69
32 Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 2005 1.69
33 The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005 1.68
34 A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 2004 1.63
35 The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 2002 1.58
36 Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer 2003 1.55
37 Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 2005 1.55
38 Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. Blood 2002 1.53
39 The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004 1.51
40 AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003 1.49
41 Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004 1.49
42 Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003 1.49
43 ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 2009 1.48
44 IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 2006 1.47
45 Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2007 1.46
46 High serum concentrations of cyclosporin related to administration of tigecycline. Eur J Clin Pharmacol 2008 1.44
47 Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004 1.41
48 Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 2006 1.40
49 Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003 1.40
50 CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009 1.38
51 Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia. Leuk Lymphoma 2006 1.37
52 A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med 2008 1.34
53 New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003 1.31
54 Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012 1.27
55 Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc Natl Acad Sci U S A 2004 1.27
56 Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2003 1.26
57 Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009 1.25
58 Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005 1.23
59 GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 2012 1.22
60 High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 2012 1.21
61 Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia. Blood 2007 1.21
62 FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood 2004 1.19
63 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003 1.18
64 Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2005 1.17
65 Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006 1.17
66 CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2013 1.16
67 Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 2013 1.15
68 Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002 1.14
69 Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 2005 1.14
70 Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002 1.12
71 Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 2005 1.11
72 Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005 1.11
73 The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006 1.11
74 Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction. Oncogene 2003 1.10
75 Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009 1.10
76 Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol 2014 1.10
77 Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 2005 1.09
78 Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009 1.07
79 KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2004 1.07
80 The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. Dtsch Arztebl Int 2009 1.07
81 Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002 1.06
82 RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica 2012 1.06
83 Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment. Mol Cell Biol 2002 1.05
84 Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248. J Biol Chem 2002 1.05
85 Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003 1.05
86 3'UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle 2009 1.04
87 Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells. Haematologica 2003 1.02
88 Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. Oncogene 2005 1.00
89 Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008 1.00
90 Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma 2009 1.00
91 Advances in the management of follicular lymphoma. Curr Opin Oncol 2012 1.00
92 The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol 2002 0.99
93 Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol 2008 0.99
94 NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009 0.98
95 Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 2003 0.98
96 Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann Hematol 2005 0.97
97 A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 2002 0.97
98 Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2013 0.97
99 Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol 2005 0.97
100 Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background. Electrophoresis 2006 0.97
101 Correlation of protein expression and gene expression in acute leukemia. Cytometry B Clin Cytom 2003 0.96
102 The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood 2012 0.95
103 Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 2002 0.95
104 Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood 2013 0.95
105 The relation between the experience of time and psychological distress in patients with hematological malignancies. Palliat Support Care 2006 0.94
106 The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2002 0.94
107 Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia. Blood 2013 0.93
108 Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol 2005 0.92
109 Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 2002 0.92
110 Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma. Genes Chromosomes Cancer 2006 0.91
111 Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient. J Clin Oncol 2009 0.91
112 Evaluating a patient's request for life-prolonging treatment: an ethical framework. J Med Ethics 2012 0.91
113 Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica 2013 0.91
114 A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma 2009 0.91
115 The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Ann Hematol 2012 0.91
116 The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease. Hum Pathol 2012 0.90
117 AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer 2005 0.90
118 Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. Haematologica 2003 0.89
119 Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol 2011 0.89
120 Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia. N Engl J Med 2004 0.89
121 Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report. J Transl Med 2009 0.88
122 The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene 2003 0.88
123 Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003 0.88
124 Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann Hematol 2012 0.88
125 Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2008 0.88
126 Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica 2004 0.88
127 Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. Haematologica 2011 0.88
128 CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One 2012 0.88
129 Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol 2007 0.87
130 FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol 2004 0.87
131 Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events. Haematologica 2005 0.87
132 Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006 0.86
133 Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood 2012 0.86
134 The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. Haematologica 2005 0.86
135 Treatment of older patients with AML. Crit Rev Oncol Hematol 2005 0.86
136 Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 2007 0.86
137 Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. Cancer Genet Cytogenet 2004 0.85
138 Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release. J Control Release 2007 0.85
139 Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol 2012 0.84
140 Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential. Blood 2007 0.84
141 Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome. Histopathology 2011 0.84
142 CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2002 0.84
143 Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. Br J Haematol 2002 0.84
144 The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. Proc Natl Acad Sci U S A 2010 0.83
145 Ethical assessment of life-prolonging treatment. Lancet Oncol 2011 0.83
146 Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 2006 0.83
147 Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene 2003 0.83
148 Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia. Hematol J 2002 0.83
149 D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. Genes Chromosomes Cancer 2006 0.83
150 Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia. Ann Hematol 2004 0.83
151 Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004 0.82
152 The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004 0.82
153 Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity. Biochem Pharmacol 2002 0.82
154 Use of polymorphisms in the noncoding region of the human mitochondrial genome to identify potential contamination of human leukemia-lymphoma cell lines. Hematol J 2004 0.81
155 Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clin Cancer Res 2008 0.81
156 Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma. Electrophoresis 2007 0.81
157 Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases. Exp Hematol 2012 0.81
158 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma. Electrophoresis 2009 0.80
159 Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. Exp Hematol Oncol 2013 0.80
160 Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy 2013 0.80
161 Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res 2006 0.80
162 Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 2002 0.79
163 High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leuk Lymphoma 2012 0.79
164 Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother Pharmacol 2007 0.79
165 Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells 2007 0.79
166 Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs 2003 0.79
167 Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response. Br J Haematol 2004 0.79
168 Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acid. Br J Haematol 2003 0.79
169 Long-term follow-up of cytogenetically normal CEBPA-mutated AML. J Hematol Oncol 2014 0.79
170 Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20. Genes Chromosomes Cancer 2011 0.78
171 Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia. Leuk Res 2006 0.78
172 A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy. Ann Hematol 2004 0.78
173 Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Curr Opin Oncol 2008 0.78
174 Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006 0.78
175 Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia. Clin Cancer Res 2005 0.78
176 Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. Leuk Lymphoma 2014 0.77
177 Metastasis of a rectal adenocarcinoma to the thyroid gland: diagnostic and therapeutic implications. Anticancer Res 2004 0.77
178 Transplantation strategies for patients with follicular lymphoma. Curr Opin Hematol 2005 0.77
179 Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma. Br J Haematol 2014 0.76
180 Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature. Leuk Res 2009 0.76
181 Current management of mantle cell lymphoma. Drugs 2007 0.76
182 Gene expression profiling as a tool for the diagnosis of acute leukemias. Semin Hematol 2003 0.76
183 Maintenance for acute myeloid leukemia revisited. Curr Treat Options Oncol 2007 0.76
184 Microenvironmental influences and antigenic stimulation in chronic lymphocytic leukemia. Onkologie 2009 0.75
185 [30. Splenomegaly: a symptom with many etiologies]. MMW Fortschr Med 2002 0.75
186 Rituximab maintenance therapy in follicular lymphoma comes of age. Leuk Res 2006 0.75
187 Treatment of AML in biological subgroups. Hematology 2005 0.75
188 [High-performance medicine and humanitarian principles]. Med Klin (Munich) 2007 0.75
189 [Pathobiology of acute myeloid leukemia]. Med Klin (Munich) 2007 0.75
190 Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia. Leuk Lymphoma 2005 0.75
191 [Complementary Therapies for Cancer]. Dtsch Med Wochenschr 2017 0.75
192 [Palliative and terminal care: doctors have to face the discussion]. Dtsch Med Wochenschr 2016 0.75
193 Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 2003 0.75
194 [Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges]. Dtsch Med Wochenschr 2017 0.75
195 Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine. Blood 2003 0.75
196 Gene expression profiling as a diagnostic tool in acute myeloid leukemia. Am J Pharmacogenomics 2004 0.75
197 Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies. Immunotherapy 2009 0.75
198 Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement. Cancer Genet Cytogenet 2003 0.75
199 Acute heart failure: when standard therapy fails--an interdisciplinary challenge. Int J Cardiol 2010 0.75
200 ["We need new alliances." Interview by Hildegrad Kaulen]. Dtsch Med Wochenschr 2006 0.75
201 [Diagnostics, classification and prognostic criteria of acute myeloid leukemia]. Med Klin (Munich) 2007 0.75
202 In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia. Ann Hematol 2007 0.75
203 Absence of SCL mutations in myeloid malignancies. Br J Haematol 2003 0.75
204 Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. Hematol J 2004 0.75
205 UGT1A7 polymorphisms, polycyclic aromatic hydrocarbons and the development of hepatocellular cancer. Hepatology 2004 0.75
206 Treatment of indolent lymphoma in Germany - results of a representative population-based survey. Clin Lymphoma Myeloma Leuk 2011 0.75
207 [Precision Oncology: Approaching the Target]. Dtsch Med Wochenschr 2017 0.75
208 Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression. Br J Haematol 2002 0.75
209 Classification of AML by DNA-oligonucleotide microarrays. Methods Mol Med 2006 0.75
210 [Current therapeutic strategies in the management of acute myeloid leukemia]. Med Klin (Munich) 2007 0.75
211 Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity. Anticancer Res 2003 0.75
212 [Therapy of acute myeloid leukemia (AML) for medically non-fit patients]. Med Klin (Munich) 2007 0.75
213 [Monoclonal antibody therapy for malignant lymphoma]. Med Klin (Munich) 2005 0.75
214 [Psycho-oncology: support for patients and family members (interview by Dr. rer. nat. Claudia Bruhn)]. Dtsch Med Wochenschr 2011 0.75
215 Proteomic analysis of transcription factor interactions in myeloid stem cell development and leukaemia. Expert Opin Ther Targets 2002 0.75
216 Investigational strategies in autologous stem cell transplantation for follicular lymphoma. Curr Oncol Rep 2006 0.75
217 Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells. Haematologica 2005 0.75